{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:37:43Z","timestamp":1786991863555,"version":"build-2736575974"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001823","name":"Ministerstvo \u0160kolstv\u00ed, Ml\u00e1de\u017ee a T\u011blov\u00fdchovy","doi-asserted-by":"publisher","award":["POLYMAT LO1507"],"award-info":[{"award-number":["POLYMAT LO1507"]}],"id":[{"id":"10.13039\/501100001823","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001824","name":"Grantov\u00e1 Agentura \u010cesk\u00e9 Republiky","doi-asserted-by":"publisher","award":["P301\/12\/1254"],"award-info":[{"award-number":["P301\/12\/1254"]}],"id":[{"id":"10.13039\/501100001824","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1016\/j.jconrel.2016.05.036","type":"journal-article","created":{"date-parts":[[2016,5,14]],"date-time":"2016-05-14T20:45:20Z","timestamp":1463258720000},"page":"136-146","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["Overcoming multidrug resistance in Dox-resistant neuroblastoma cell lines via treatment with HPMA copolymer conjugates containing anthracyclines and P-gp inhibitors"],"prefix":"10.1016","volume":"233","author":[{"given":"Eva","family":"Koziolov\u00e1","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Janou\u0161kov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucie","family":"Cuchalov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuzana","family":"Hv\u011bzdov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Hrab\u011bta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom\u00e1\u0161","family":"Eckschlager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ladislav","family":"Siv\u00e1k","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karel","family":"Ulbrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom\u00e1\u0161","family":"Etrych","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladim\u00edr","family":"\u0160ubr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2016.05.036_bb0005","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1200\/JCO.1999.17.7.2264","article-title":"Molecular biology of neuroblastoma","volume":"17","author":"Maris","year":"1999","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2016.05.036_bb0010","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/nrc706","article-title":"Multidrug resistance in cancer: role of ATP-dependent transporters","volume":"2","author":"Gottesman","year":"2002","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jconrel.2016.05.036_bb0015","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1146\/annurev.pharmtox.39.1.361","article-title":"Biochemical, cellular, and pharmacological aspects of the multidrug transporter","volume":"39","author":"Ambudkar","year":"1999","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.jconrel.2016.05.036_bb0020","doi-asserted-by":"crossref","first-page":"4374","DOI":"10.1021\/acs.biochem.5b00018","article-title":"Multiple drug transport pathways through human P-glycoprotein","volume":"54","author":"McCormick","year":"2015","journal-title":"Biochemistry"},{"key":"10.1016\/j.jconrel.2016.05.036_bb0025","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0889-8588(18)30097-2","article-title":"Mdr expression in normal-tissues \u2014 pharmacological implications for the clinical use of P-glycoprotein Inhibitors","volume":"9","author":"Lum","year":"1995","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"10.1016\/j.jconrel.2016.05.036_bb0030","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1517\/13543784.2012.679339","article-title":"Investigational ABC transporter inhibitors","volume":"21","author":"Falasca","year":"2012","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.jconrel.2016.05.036_bb0035","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/0959-8049(96)00091-3","article-title":"Clinical trials of P-glycoprotein reversal in solid tumours","volume":"32A","author":"Ferry","year":"1996","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.jconrel.2016.05.036_bb0040","doi-asserted-by":"crossref","first-page":"570","DOI":"10.2174\/138920111795164048","article-title":"Revisiting the ABCs of multidrug resistance in cancer chemotherapy","volume":"12","author":"Tiwari","year":"2011","journal-title":"Curr. Pharm. Biotechnol."},{"key":"10.1016\/j.jconrel.2016.05.036_bb0045","first-page":"193","article-title":"Tumoritropic and lymphotropic principles of macromolecular drugs","volume":"6","author":"Maeda","year":"1989","journal-title":"crit. Rev. Ther. Drug Carrier Syst."},{"key":"10.1016\/j.jconrel.2016.05.036_bb0050","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1517\/17425247.2015.960920","article-title":"Overcoming multidrug resistance with nanomedicines","volume":"12","author":"Ganoth","year":"2015","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.jconrel.2016.05.036_bb0055","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1016\/j.addr.2013.09.018","article-title":"Multidrug resistance: physiological principles and nanomedical solutions","volume":"65","author":"Kunjachan","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2016.05.036_bb0060","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2174\/0929867322666151006094559","article-title":"Engineering nanomedicines to overcome multidrug resistance in cancer therapy","volume":"23","author":"Beretta","year":"2016","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.jconrel.2016.05.036_bb0065","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/S0959-8049(01)00421-X","article-title":"HPMA-hydrogels result in prolonged delivery of anticancer drugs and are a promising tool for the treatment of sensitive and multidrug resistant leukaemia","volume":"38","author":"\u0160tastn\u00fd","year":"2002","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.jconrel.2016.05.036_bb0070","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.ijpharm.2011.05.082","article-title":"Reversal of multidrug resistance by co-delivery of tariquidar (XR9576) and paclitaxel using long-circulating liposomes","volume":"416","author":"Patel","year":"2011","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2016.05.036_bb0075","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jconrel.2009.01.021","article-title":"Nanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance","volume":"136","author":"Patil","year":"2009","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2016.05.036_bb0080","doi-asserted-by":"crossref","first-page":"3030","DOI":"10.1021\/bm500649q","article-title":"Synthesis of poly[N-(2-hydroxypropyl)methacrylamide] conjugates of inhibitors of the ABC transporter that overcome multidrug resistance in doxorubicin-resistant P388 cells in vitro","volume":"15","author":"\u0160ubr","year":"2014","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.jconrel.2016.05.036_bb0085","first-page":"1697","article-title":"Cellular uptake and efflux and cytostatic activity of 4\u2032-O-tetrahydropyranyladriamycin in adriamycin-sensitive and resistant tumor-cell lines","volume":"37","author":"Kunimoto","year":"1984","journal-title":"J. Anthropol."},{"key":"10.1016\/j.jconrel.2016.05.036_bb0090","first-page":"312","article-title":"Rapid uptake by cultured tumor-cells and intracellular behavior of 4\u2032-O-tetrahydropyranyladriamycin","volume":"36","author":"Kunimoto","year":"1983","journal-title":"J. Anthropol."},{"key":"10.1016\/j.jconrel.2016.05.036_bb0095","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1111\/j.1349-7006.1999.tb00814.x","article-title":"Membrane transport and antitumor activity of pirarubicin, and comparison with those of doxorubicin","volume":"90","author":"Sugiyama","year":"1999","journal-title":"Jpn. J. Cancer Res."},{"key":"10.1016\/j.jconrel.2016.05.036_bb0100","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s11523-015-0379-4","article-title":"HPMA copolymer-conjugated pirarubicin in multimodal treatment of a patient with stage IV prostate cancer and extensive lung and bone metastases","volume":"11","author":"Dozono","year":"2016","journal-title":"Target. Oncol."},{"key":"10.1016\/j.jconrel.2016.05.036_bb0105","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1139\/y02-132","article-title":"Relation between MDR1 mRNA levels, resistance factor, and the efficiency of P-glycoprotein-mediated efflux of pirarubicin in multidrug-resistant K562 sublines","volume":"80","author":"Meesungnoen","year":"2002","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"10.1016\/j.jconrel.2016.05.036_bb0110","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.cdp.2004.02.005","article-title":"The activity of latent benzoperimidine esters to inhibit P-glycoprotein and multidrug resistance-associated protein 1 dependent efflux of pirarubicin from several lines of multidrug resistant tumor cells","volume":"28","author":"Glowacka-Rogacka","year":"2004","journal-title":"Cancer Detect. Prev."},{"key":"10.1016\/j.jconrel.2016.05.036_bb0115","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1016\/j.cellsig.2015.09.014","article-title":"DAB2IP regulates the chemoresistance to pirarubicin and tumor recurrence of non-muscle invasive bladder cancer through STAT3\/Twist1\/P-glycoprotein signaling","volume":"27","author":"Wu","year":"2015","journal-title":"Cell. Signal."},{"key":"10.1016\/j.jconrel.2016.05.036_bb0120","first-page":"967","article-title":"Pirarubicin might partly circumvent the P-glycoprotein-mediated drug resistance of human breast cancer tissues","volume":"18","author":"Kubota","year":"1998","journal-title":"Anticancer Res."},{"key":"10.1016\/j.jconrel.2016.05.036_bb0125","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/BF02967534","article-title":"Resistant mechanisms of anthracyclines\u2013pirarubicin might partly break through the P-glycoprotein-mediated drug-resistance of human breast cancer tissues","volume":"8","author":"Kubota","year":"2001","journal-title":"Breast Cancer"},{"key":"10.1016\/j.jconrel.2016.05.036_bb0130","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/S0167-4889(99)00060-9","article-title":"Correlation between the kinetics of anthracycline uptake and the resistance factor in cancer cells expressing the multidrug resistance protein or the P-glycoprotein","volume":"1450","author":"Marbeuf-Gueye","year":"1999","journal-title":"Biochim. Biophys. Acta, Mol. Cell Res."},{"key":"10.1016\/j.jconrel.2016.05.036_bb0135","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1002\/macp.201100632","article-title":"Hydrolytically degradable polymer micelles for anticancer drug delivery to solid tumors","volume":"213","author":"Chytil","year":"2012","journal-title":"Macromol. Chem. Phys."},{"key":"10.1016\/j.jconrel.2016.05.036_bb0140","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1002\/app.28466","article-title":"N-(2-hydroxypropyl)methacrylamide-based polymer conjugates with pH-controlled activation of doxorubicin. I. New synthesis, physicochemical characterization and preliminary biological evaluation","volume":"109","author":"Etrych","year":"2008","journal-title":"J. Appl. Polym. Sci."},{"key":"10.1016\/j.jconrel.2016.05.036_bb0145","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0168-3659(01)00281-4","article-title":"New HPMA copolymers containing doxorubicin bound via pH-sensitive linkage: synthesis and preliminary in vitro and in vivo biological properties","volume":"73","author":"Etrych","year":"2001","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2016.05.036_bb0150","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jconrel.2013.11.011","article-title":"Two step mechanisms of tumor selective delivery of N-(2-hydroxypropyl)methacrylamide copolymer conjugated with pirarubicin via an acid-cleavable linkage","volume":"174","author":"Nakamura","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2016.05.036_bb0155","first-page":"415","article-title":"Characterization of drug-resistant neuroblastoma cell lines by comparative genomic hybridization","volume":"52","author":"Bedrn\u00ed\u010dek","year":"2005","journal-title":"Neoplasma"},{"key":"10.1016\/j.jconrel.2016.05.036_bb0160","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1186\/1471-2407-6-294","article-title":"Chemoresistance induces enhanced adhesion and transendothelial penetration of neuroblastoma cells by down-regulating NCAM surface expression","volume":"6","author":"Blaheta","year":"2006","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jconrel.2016.05.036_bb0165","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2-\u0394\u0394CT method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"issue":"Suppl. 1","key":"10.1016\/j.jconrel.2016.05.036_bb0170","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.33549\/physiolres.933137","article-title":"The comparison of in vivo properties of water-soluble HPMA-based polymer conjugates with doxorubicin prepared by controlled RAFT or free radical polymerization","volume":"64","author":"Chytil","year":"2015","journal-title":"Physiol. Res."},{"key":"10.1016\/j.jconrel.2016.05.036_bb0175","first-page":"1194","article-title":"Cellular pH gradient in tumor versus normal tissue: potential exploitation for the treatment of cancer","volume":"56","author":"Gerweck","year":"1996","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2016.05.036_bb0180","series-title":"Controlled Drug Delivry","first-page":"581","article-title":"Selective endocytosis of macromolecular drug carriers","year":"1987"},{"key":"10.1016\/j.jconrel.2016.05.036_bb0185","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/00043426-199205000-00004","article-title":"Molecular-basis of clinical heterogeneity in neuroblastoma","volume":"14","author":"Brodeur","year":"1992","journal-title":"Am. J. Pediatric Hematol. Oncol."},{"key":"10.1016\/j.jconrel.2016.05.036_bb0190","article-title":"Pronounced cellular uptake of pirarubicin in comparison with other anthracycline conjugates in the HPMA copolymer of pirarubicin and doxorubicin","author":"Nakamura","year":"2016","journal-title":"Biomaterials"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365916303169?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365916303169?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,6,26]],"date-time":"2022-06-26T07:39:04Z","timestamp":1656229144000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365916303169"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":38,"alternative-id":["S0168365916303169"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2016.05.036","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Overcoming multidrug resistance in Dox-resistant neuroblastoma cell lines via treatment with HPMA copolymer conjugates containing anthracyclines and P-gp inhibitors","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2016.05.036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}